This Article Full Text Full Text (PDF) All Versions of this Article: 48/1/51    most recent 01.HYP.0000225402.69580.1dv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Araki, K. Articles by Yoshimatsu, H. Search for Related Content PubMed PubMed Citation Articles by Araki, K. Articles by Yoshimatsu, H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Obesity Related Collections Obesity Type 2 diabetes

(Hypertension. 2006;48:51.)
© 2006 American Heart Association, Inc.

Original Articles

Telmisartan Prevents Obesity and Increases the Expression of Uncoupling Protein 1 in Diet-Induced Obese Mice

Kana Araki; Takayuki Masaki; Isao Katsuragi; Katsuhiro Tanaka; Tetsuya Kakuma; Hironobu Yoshimatsu

From the Department of Internal Medicine 1, Faculty of Medicine, Oita University, Japan.

Correspondence to Hironobu Yoshimatsu, MD, PhD, Department of Internal Medicine 1, Faculty of Medicine, Oita University, 1-1 Idai-ga-oka, Hasama, Oita 879-5593 Japan. E-mail ka_na.a{at}med.oita-u.ac.jp

The aim of the present study was to clarify the effect of telmisartan, an angiotensin II receptor blocker, on the development of obesity and related metabolic disorders in diet-induced obese mice. Treatment with telmisartan dissolved in drinking water at a dosage of 5 mg/kg per day for 14 days attenuated the diet-induced weight gain without affecting food intake in diet-induced obese mice compared with controls using nontreated water. Telmisartan treatment decreased the weight of visceral adipose tissue and the triglyceride content in the liver and skeletal muscle. In addition, hyperglycemia, hyperinsulinemia, and hypertriglyceridemia in diet-induced obese mice all improved with telmisartan treatment. Furthermore, telmisartan treatment increased adiponectin mRNA in visceral white adipose tissue and was associated with a concomitant change in the serum adiponectin level. In contrast, the treatment reduced the serum level of resistin. Finally, telmisartan treatment increased the mRNA expression of uncoupling protein 1 in brown adipose tissue and was accompanied by an increase in oxygen consumption. In conclusion, telmisartan treatment might prevent the development of obesity and related metabolic disorders by altering the levels of adiponectin, resistin, and uncoupling protein 1 in diet-induced obese mice. Our results indicate that telmisartan can be used as a therapeutic tool for metabolic syndrome, including visceral obesity.

Key Words: obesity • hypertension, obesity • metabolism • insulin resistance • adipose tissue

This article has been cited by other articles:

				E. M. de Cavanagh, M. Ferder, F. Inserra, and L. Ferder Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H550 - H558. [Abstract] [Full Text] [PDF]

				P. Gratze, M. Boschmann, R. Dechend, F. Qadri, J. Malchow, S. Graeske, S. Engeli, J. Janke, J. Springer, A. Contrepas, et al. Energy Metabolism in Human Renin-Gene Transgenic Rats: Does Renin Contribute to Obesity? Hypertension, March 1, 2009; 53(3): 516 - 523. [Abstract] [Full Text] [PDF]

				C. Roberge, A. C. Carpentier, M.-F. Langlois, J.-P. Baillargeon, J.-L. Ardilouze, P. Maheux, and N. Gallo-Payet Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1465 - E1478. [Abstract] [Full Text] [PDF]